Last updated: February 20, 2026
What is NDC 43547-0033?
NDC 43547-0033 is the National Drug Code identifier for Rituximab (brand name Rituxan), a monoclonal antibody used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Market Overview
The Rituximab market is characterized by high demand in oncology and autoimmune indications. Adoption driven by expanding indication approvals and biosimilar entry impacts pricing and market share.
Current Market Size
In 2022, the global Rituximab market was valued at approximately $7.2 billion. The US accounted for roughly 60% of this figure, equating to $4.32 billion. The growth rate was around 4.8% CAGR from 2018 to 2022.
Key Players
| Company |
Product (Brand Name) |
Estimated Market Share (2022) |
Notable Patents/Licensing |
Notes |
| Roche |
Rituxan |
~85% |
Patents until 2024 |
Market leader, biosimilar introduction ongoing |
| Teva, Samsung, Celltrion |
Truxima (biosimilar) |
~10% |
Biosimilar approvals in US/Europe |
Growing segment |
| Other bidders |
Ruxience, etc. |
~5% |
Biosimilar variants |
Market entry varies by region |
Market Drivers
- Increased approval for autoimmune conditions (e.g., rheumatoid arthritis, granulomatosis with polyangiitis).
- Expanded indications in oncology, including first-line non-Hodgkin lymphoma.
- Biosimilar presence leading to price competition.
Market Challenges
- Patent expiration (Roche's patents extended to 2024).
- Competition from biosimilars reducing prices and market share.
- Reimbursement policies influencing prescribing patterns.
Pricing Dynamics
Current Wholesale Acquisition Cost (WAC)
| Region |
Typical Price per Vial |
Notes |
| United States |
$4,200 to $4,600 |
Prices vary by dosage and supplier |
| European Union |
€3,600 to €4,000 |
Exchange rate dependent |
| Rest of World |
$2,500 to $3,500 |
Generally lower, depending on country |
Biosimilar Pricing Impact
- Biosimilar versions (~$2,500–$3,000 per vial) reduce average price points.
- Traditionally, biosimilar uptake in the US is slower due to market access and reimbursement hurdles but is increasing.
Price Projections (Next 3–5 Years)
| Year |
Projected Average Price per Vial |
Drivers |
| 2023 |
$4,200–$4,600 |
Market maturation, patent expiry near-term |
| 2024 |
$3,800–$4,300 |
Biosimilar market penetration increases |
| 2025 |
$3,700–$4,000 |
Widespread biosimilar adoption, price competition |
Assumptions: Prices decline with biosimilar market entry but stabilize as patent protections phase out. Price erosion is expected to be around 5–10% annually post-2024.
Competitive and Regulatory Landscape
- Biosimilar approvals in the US began in 2017; entry accelerates as patents expire.
- FDA approved the first Rituximab biosimilar in 2017; multiple have followed.
- Payers and providers increasingly favor biosimilar use for cost containment.
Summary
| Aspect |
Data Summary |
| Total Market |
$7.2 billion (2022) |
| US Market Share |
~60% ($4.32 billion) |
| Patents Expiry |
2024 (patents expiring in the US) |
| Average Price per Vial |
$4,200–$4,600 (2023 estimate) |
| Biosimilar Impact |
Prices may drop to $2,500–$3,000 per vial |
Key Takeaways
- The market for NDC 43547-0033 (Rituximab) remains sizable with steady growth projected as biosimilars gain market share.
- Prices are declining primarily due to biosimilar competition, with forecasts indicating a 10–15% reduction post-2024.
- Strategic positioning will depend on biosimilar adoption and patent landscape developments.
FAQs
-
When will the patents for Rituxan expire?
Patents are scheduled to expire in the US in 2024, opening the market for biosimilar competition.
-
How much will biosimilar versions reduce Rituximab prices?
Biosimilars are expected to reduce prices by approximately 30–50%, bringing costs down to about $2,500–$3,000 per vial.
-
What are the key indications for Rituximab?
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis.
-
What regions are leading in Rituximab sales?
The US leads with over 60% of the global market; Europe follows with significant shares.
-
How will regulatory policies influence future pricing?
Reimbursement policies favoring biosimilars may accelerate price declines; approval pathways for biosimilars are streamlined in some regions, impacting competition.
References
[1] IQVIA. (2022). Global Oncology & Hematology Market Report.
[2] FDA. (2022). Biosimilar Product Information.
[3] EvaluatePharma. (2022). Prescription Drug Market Outlook.
[4] GlobalData. (2022). Biosimilar Pharma Forecasts.
[5] American Hospital Association. (2022). Reimbursement and Formularies Report.
